Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria

Autor(es)

Roque-Borda, Cesar Augusto ^[1] ; da Silva, Patricia Bento ^[2] ; Rodrigues, Mosar Correa ^[2] ; Azevedo, Ricardo Bentes ^[2] ; Di Filippo, Leonardo ^[3] ; Duarte, Jonatas L. ^[3] ; Chorilli, Marlus ^[3] ; Vicente, Eduardo Festozo ^[4] ; Pavan, Fernando Rogerio ^[1]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, TB Res Lab, BR-14800903 Araraquara, SP - Brazil

^[2] Univ Brasilia, Inst Biol Sci, Dept Genet & Morphol, Lab Nanobiotechnol, BR-70910900 Brasilia, DF - Brazil

^[3] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Dept Drugs & Med, BR-14800903 Araraquara, SP - Brazil

^[4] Sao Paulo State Univ UNESP, Sch Sci & Engn, BR-17602496 Tupa - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: PHARMACEUTICS; v. 13, n. 6 JUN 2021.
• Citações Web of Science: 1

Resumo

Bacterial resistance has intensified in recent years due to the uncontrolled use of conventional drugs, and new bacterial strains with multiple resistance have been reported. This problem may be solved by using antimicrobial peptides (AMPs), which fulfill their bactericidal activity without developing much bacterial resistance. The rapid interaction between AMPs and the bacterial cell membrane means that the bacteria cannot easily develop resistance mechanisms. In addition, various drugs for clinical use have lost their effect as a conventional treatment; however, the synergistic effect of AMPs with these drugs would help to reactivate and enhance antimicrobial activity. Their efficiency against multi-resistant and extensively resistant bacteria has positioned them as promising molecules to replace or improve conventional drugs. In this review, we examined the importance of antimicrobial peptides and their successful activity against critical and high-priority bacteria published in the WHO list. (AU)

• Processo FAPESP: 20/16573-3 - Estudos in vitro e in vivo de análogos do peptídeo antimicrobiano B1CTcu5 encapsulados em micropartículas colón-específicas frente ao Mycobacterium tuberculosis
• Beneficiário: Cesar Augusto Roque Borda
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 18/25707-3 - Aplicação do peptídeo antimicrobiano Ctx(Ile21)-Ha e seus conjugados em diferentes formulações como aditivo nutricional em pintainhas de postura
• Beneficiário: Cesar Augusto Roque Borda
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 20/13497-4 - Busca do mecanismo de ação e efeito terapêutico de novas classes de fármacos contra Mycobacterium tuberculosis
• Beneficiário: Fernando Rogério Pavan
• Modalidade de apoio: Auxílio à Pesquisa - Regular